Details

Autor(en) / Beteiligte

• Videm, Vibeke
• Wiseth, Rune
• Gunnes, Sigurd
• Madsen, Hans O
• Garred, Peter

Titel

Multiple inflammatory markers in patients with significant coronary artery disease

Ist Teil von

• International journal of cardiology, 2007-05, Vol.118 (1), p.81-87

Ort / Verlag

Shannon: Elsevier Ireland Ltd

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Background Several inflammatory biomarkers are linked to cardiovascular risk. In order to investigate their coexistence and relative responses, several established and two novel markers (lactoferrin and the terminal complement complex), representing infection and central components of inflammation, were measured simultaneously in patients undergoing first-time coronary angiography. Methods and results Blood samples from patients with ( n = 131) or without ( n = 103) significant coronary artery stenosis were analyzed for plasma markers representing endothelium, platelets, neutrophils, monocytes, and complement, C-reactive protein, and antibodies against the infectious agents Chlamydia pneumoniae , Helicobacter pylori , and cytomegalovirus. In multivariate logistic regression analysis, hypercholesterolemia ( p < 0.001), increased concentrations of the neutrophil activation marker lactoferrin ( p < 0.001) and the monocyte activation marker neopterin ( p = 0.012), lower concentrations of the terminal complement complex ( p < 0.001), and antibodies against C. pneumoniae ( p = 0.023) were variables linked to coronary artery stenosis. In univariate analysis additional relationships were found to current smoking ( p < 0.001), increased plasma concentrations of vascular cell adhesion molecule-1 ( p = 0.015), E-selectin ( p < 0.01), myeloperoxidase ( p = 0.051) and endothelin-1 ( p = 0.053), as well as diabetes ( p = 0.039). Conclusions Activation of multiple inflammatory pathways and C. pneumoniae infection may influence the inflammatory response in atherosclerosis. These pilot data provide an indication of the relative usefulness of various inflammatory biomarkers, indicating that the novel markers lactoferrin and the terminal complement complex warrant further investigation.